Hormone modulator guide
General

Finasteride

Finasteride is an oral 5α-reductase inhibitor prescribed to treat male pattern hair loss (1 mg) and benign prostatic hyperplasia (5 mg). It lowers DHT levels, producing measurable clinical benefit over months but carries sexual side-effect risks and reproductive cautions.

5-alpha-reductase inhibitor
Finasterid
Propecia
Proscar

This guide covers all common forms and variations of finasteride in one place. Use the sections below to find the form that fits your situation.

How it works in the body

Finasteride is a competitive, reversible inhibitor of 5α-reductase type II, the enzyme that converts testosterone into the more potent androgen dihydrotestosterone (DHT). By lowering tissue and serum DHT, finasteride reduces androgenic stimulation in two primary target tissues.

In the prostate, reduced intraprostatic DHT leads to gland shrinkage over months, lowering urethral obstruction and the risk of BPH progression in appropriately selected men. In scalp hair follicles, lower DHT slows or reverses follicular miniaturization in androgen-sensitive regions, preserving existing hair and enabling modest regrowth in men with androgenetic alopecia.

Finasteride does not substantially raise or lower circulating testosterone in most men. Its therapeutic effects and androgen-related adverse effects are both explained by DHT reduction rather than changes in testosterone.

Finasteride molecular structure
2D molecular structure from PubChem, National Library of Medicine.

Body systems

Endocrine system
Reproductive system
Hair follicles
Urinary tract / prostate

Associated molecules

Dihydrotestosterone (DHT)
Testosterone
5α-reductase (type II)

Track it lightly

If you're considering finasteride, document baseline sexual function, scalp photos, and PSA (if relevant) before starting. Tracking these markers over time makes it easier to assess both benefit and side effects.

Trying this? Start tracking it here.

Background

Finasteride was developed in the 1980s and first approved at the 5 mg dose for benign prostatic hyperplasia. Clinical investigation then demonstrated that 1 mg daily was effective for male pattern hair loss, leading to a separate approval for that indication. Merck introduced both formulations commercially in the 1990s. Post-marketing surveillance has since identified uncommon but clinically significant signals related to sexual function and reproductive safety, prompting label updates and ongoing research.

Evidence snapshot

For male pattern hair loss, randomized controlled trials of oral finasteride 1 mg daily show greater hair count and patient-rated improvement versus placebo, with effects detectable by 3 months and more pronounced at 6–12 months. This evidence base supported regulatory approval for androgenetic alopecia in men.

For benign prostatic hyperplasia (BPH), trials of finasteride 5 mg daily demonstrate reduced prostate volume, improved urinary symptoms in men with larger prostates, and lower rates of acute urinary retention and surgical intervention over multi-year follow-up. Finasteride suppresses circulating PSA by roughly 40–60% after several months of therapy, requiring adjusted interpretation of PSA results.

Sexual adverse effects — decreased libido, erectile dysfunction, ejaculatory disorders — occur at rates higher than placebo in randomized trials but remain uncommon overall. Post-marketing case series describe persistent sexual symptoms after discontinuation in a subset of users; causality, incidence, and mechanism are under active investigation.

Finasteride is teratogenic to a male fetus. Use in women who are or may become pregnant is contraindicated, and handling of crushed or broken tablets by such women is discouraged. Serious organ toxicity is uncommon in long-term follow-up, but reproductive and mood-related signals continue to be monitored.

Pharmacokinetics & bioavailability

Finasteride is well absorbed orally, reaching peak plasma concentrations within 1–2 hours. It is hepatically metabolized via oxidation and has a plasma half-life of approximately 5–8 hours in younger men and somewhat longer in older men; steady state is reached within a few days of daily dosing. The drug concentrates in prostate and scalp tissues where 5α-reductase type II is expressed. Topical formulations are under clinical investigation to limit systemic exposure but are not standard in most regulatory approvals.

Populations studied and clinical efficacy

Randomized, placebo-controlled trials have evaluated finasteride 1 mg in adult men with male pattern hair loss and 5 mg in men with symptomatic prostatic enlargement. Efficacy data in women are limited; use in women of childbearing potential is contraindicated because of teratogenic risk. For BPH, men with larger baseline prostate volumes show greater benefit than those with small prostates.

Long-term safety and post-marketing signals

Long-term trial extensions report continued efficacy and largely stable adverse event profiles. Post-marketing reports and observational studies have described persistent sexual adverse effects in a subset of users after stopping therapy — sometimes termed post-finasteride syndrome. Causality and mechanism remain debated, and evidence is mixed. Monitoring sexual function and mood during therapy is clinically appropriate.

Monitoring, PSA interpretation, and regulatory guidance

Because finasteride suppresses circulating PSA by approximately half, clinicians should obtain a baseline PSA before starting therapy and document that the patient is on finasteride when interpreting subsequent values. Regulatory labeling requires clear disclosure of reproductive risks: women who are pregnant or may become pregnant must avoid contact with crushed or broken tablets, and finasteride is contraindicated in this population.

Compound variations

Finasteride 1 mg (Propecia)

Finasteride

Approved dose for male pattern hair loss; daily oral tablet that reduces scalp DHT to slow hair loss with the possibility of modest regrowth.

Common use case

Men with androgenetic alopecia seeking to slow hair loss and achieve modest regrowth.

Dosage note

1 mg orally once daily; allow 3–12 months to assess clinical effect; continue long-term to maintain gains.

Finasteride 5 mg (Proscar)

Finasteride

Higher-dose formulation used for benign prostatic hyperplasia to reduce prostate volume and lower the risk of urinary complications over months of therapy.

Common use case

Men with symptomatic BPH and enlarged prostates where 5α-reductase inhibition is indicated.

Dosage note

5 mg orally once daily; benefits emerge over 6–12 months; monitor PSA and urinary symptoms.

Topical finasteride (investigational)

Finasteride

Topical formulations aim to deliver drug to the scalp while limiting systemic absorption; clinical data are emerging but not standardized across products.

Common use case

Men seeking localized scalp DHT reduction or wishing to minimize systemic exposure; availability and regulatory status vary by country.

Dosage note

Formulation-dependent; follow product-specific guidance and confirm local regulatory approval status.

Dutasteride (related 5α-reductase inhibitor)

Finasteride

Dutasteride inhibits both type I and type II 5α-reductase isoenzymes, suppressing DHT more completely than finasteride; approved for BPH and studied off-label for hair loss.

Common use case

Situations where greater DHT suppression is desired; often considered when finasteride response is inadequate.

Dosage note

0.5 mg orally once daily for approved BPH indications; not interchangeable with finasteride without clinician guidance.

Dosage and best practices

Dosage principles

  • Male pattern hair loss: 1 mg orally once daily. Clinical trials show onset of effect at approximately 3 months; maximal benefit typically by 6–12 months. Long-term continuous use is required to maintain benefit; hair loss resumes after cessation.
  • Benign prostatic hyperplasia: 5 mg orally once daily. Reductions in prostate size and risk of acute urinary retention or surgery accrue over 6–12 months of therapy.
  • PSA monitoring: serum PSA falls approximately 40–60% within 6–12 months. When interpreting PSA in men on finasteride, establish a pre-treatment baseline and account for suppression; some guidelines recommend doubling the measured value as an estimate of underlying PSA.

Best practices

  • Baseline assessment: document sexual function and PSA (if age-appropriate) before starting finasteride.
  • Set expectations: explain that hair and BPH benefits take months to emerge and that stopping treatment reverses gains.
  • Reproductive caution: men should not donate blood while on finasteride if the recipient could be pregnant; women who are or may become pregnant must not handle crushed or broken tablets.

Literature and references

Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group

Journal of the American Academy of Dermatology • 1998

In two 1-year placebo-controlled trials of 1553 men aged 18 to 41 with male pattern hair loss, oral finasteride 1 mg/d improved scalp hair by all evaluation methods at 1 and 2 years.

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group

The New England journal of medicine • 1998

Double-blind, randomized, placebo-controlled trial of 3040 men with moderate-to-severe urinary symptoms and enlarged prostates given 5 mg finasteride daily or placebo for four years.

Persistent sexual side effects of finasteride for male pattern hair loss

The journal of sexual medicine • 2011

Survey study describing persistent sexual symptoms after stopping finasteride in a sample of men; highlights post-marketing concerns and the need for controlled study to establish causality and incidence.

FDA Drug Safety Communication: 5-alpha reductase inhibitors (5-ARIs) may increase the risk of a more serious form of prostate cancer

U.S. Food and Drug Administration (Safety Communication) • 2012

Regulatory communication describing label updates for finasteride and dutasteride, including sexual side-effect signals, reproductive precautions, and prostate cancer risk findings.

The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia

The New England journal of medicine • 2003

Double-blind trial in 3047 men (mean follow-up 4.5 years) found doxazosin and finasteride reduced the risk of overall clinical progression of benign prostatic hyperplasia by 39 and 34 percent.

Common questions

Can women take finasteride?

Finasteride is contraindicated in women who are or may become pregnant because of the risk of genital abnormalities in a male fetus. Evidence for female pattern hair loss is limited and inconsistent; finasteride is not approved for women of childbearing potential.

How long before I see results for hair loss?

Clinical trials report detectable changes at approximately 3 months, with more substantial benefit at 6–12 months. Daily use must continue to maintain gains; hair shedding typically resumes after stopping treatment.

Are sexual side effects permanent?

In most randomized trials, sexual side effects occur in a minority of users and resolve after stopping. Observational reports describe persistent symptoms in some men after discontinuation; incidence, causation, and mechanisms are not fully established.

Does finasteride affect prostate cancer risk?

Large trials show finasteride reduces overall prostate cancer incidence, but some analyses found a small increase in detection of high-grade tumors — an association complicated by PSA suppression and detection bias. Clinical guidelines address this tradeoff when finasteride is considered for prostate disease.

Can I use finasteride with topical minoxidil?

Yes. Oral finasteride and topical minoxidil act through different mechanisms and are frequently combined for male pattern hair loss. Combined use is common in clinical practice.